Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The Coartem Story: Novartis Workers In NY Feel Uplift In Battling Malaria

Executive Summary

On New Year's Eve in 2005, the operators of Novartis' plant in Suffern, N.Y. were jubilant. The facility had just manufactured its 20 millionth treatment of Coartem (artemether/lumefantrine)

You may also be interested in...



Seeking New Opportunities For Traditional Chinese Medicine

A joint venture between Nestle Health and Hutchison China MediTech is amid an ongoing Phase III trial hoping to validate traditional Chinese medicine for Western health care systems. New reports of TCM contamination in China offer a glimpse of opportunity for Western entries.

Seeking New Opportunities For Traditional Chinese Medicine

A joint venture between Nestle Health and Hutchison China MediTech is amid an ongoing Phase III trial hoping to validate traditional Chinese medicine for Western health care systems. New reports of TCM contamination in China offer a glimpse of opportunity for Western entries.

Novartis Typhoid Vaccine Seeks Partner After Securing Pakistan Clinical Trial Site

Phase II study is ongoing in Pakistan, a year after Novartis convinced the Pakistani government to lift its ban on clinical trials. Antimalarials with a different mechanism of action than Coartem are in Phase I and II trials.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS051200

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel